Companies Kyntra BIO
Kyntra BIO (FGEN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Kyntra BIO’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,642,113FY2024
- $2,113,842FY2025
CEO total pay was $2,113,842 in fiscal 2025, down from $2,642,113 in fiscal 2024.
FY2025: salary $665,000 · bonus $0 · stock awards $0 · option awards $846,023
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Thane Wettig | $665,000 | $0 | $0 | $846,023 | $580,545 | $0 | $22,274 | $2,113,842 |
| Chief Executive Officer and Director | ||||||||
| Christine Chung | 515,000 | 0 | 0 | 0 | 0 | 0 | 666,108 | 1,181,108 |
| former Senior Vice President, China Operations | ||||||||
| David DeLucia | 450,000 | 40,000 | 0 | 341,653 | 209,952 | 0 | 69,393 | 1,110,999 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Thane Wettig | $2,113,842 | $2,642,113 | — | ↓ −528,271 |
| Christine Chung | 1,181,108 | 1,175,838 | — | ↑ +5,270 |
| David DeLucia | 1,110,999 | 686,152 | — | ↑ +424,847 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
In 2025, our executive compensation program consisted of base salary, an annual cash bonus target, and long-term incentive compensation in the form of stock options. While our Compensation Committee does not have any formal policies for allocating compensation among the three components, our Compensation Committee reviews relevant market compensation data and uses its judgment to determine the appropriate level and mix of compensation on an annual basis to ensure that our compensation is competitive and that we are able to attract and retain capable named executive officers to work for our long-term prosperity and stockholder value, without taking unnecessary or excessive risks.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Thane Wettig | RSU | 2025-01-09 | — | — | 51,999 | — | $846,023 |
| David DeLucia | RSU | 2025-01-09 | — | — | 20,999 | — | 341,653 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Thane Wettig | $846,023 | $0 | $0 | 0.0% |
| David DeLucia | 341,653 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Thane Wettig | Option | 187 | 390 | — |
| David DeLucia | Option | 205 | 249.75 | — |
| Thane Wettig | PSU | 675 | — | 5,926 |
| David DeLucia | Option | 990 | 47.25 | — |
| David DeLucia | Option | 1,749 | 30.25 | — |
| Thane Wettig | RSU | 3,735 | — | 32,793 |
| Thane Wettig | Option | 5,249 | 44.25 | — |
| David DeLucia | Option | 17,062 | 16.27 | — |
| Thane Wettig | Option | 18,765 | 42.88 | — |
| Thane Wettig | Option | 42,250 | 16.27 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James A. SchoeneckIndependent · Board Chair · Audit · Compensation (Chair) · Nominating/Governance (Chair) | $137,500 | $0 | $36,612 | — | $0 | $174,112 |
| Jeffrey L. EdwardsIndependent · Audit (Chair) · Nominating/Governance | 75,000 | 0 | 36,612 | — | 0 | 111,612 |
| Maykin HoIndependent | 60,000 | 0 | 36,612 | — | 0 | 96,612 |
| Michael KauffmanIndependent · Audit · Compensation · Newly elected | 33,757 | 0 | 57,969 | — | 0 | 91,726 |
| Aoife BrennanIndependent · Departed during FY | 24,643 | 0 | — | — | 0 | 24,643 |
| Thane WettigEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 17,500 / 10,000 |
| Stock ownership guideline | Due to the Company effecting a reverse stock split in June 2025, we have currently paused the stock ownership guidelines for directors and officers. |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $330,900 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $330,900 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Kyntra BIO as a peer
Companies that benchmark against FGEN
The list of companies that name FGEN as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Eagle Pharmaceuticals | 2022 | Scott Tarriff | $848,940 | $9,011,197 | $0 | $636,705 | $10,520,577 |
| 2 | SAB Biotherapeutics | 2025 | Samuel Reich | 525,000 | — | 8,588,160 | 315,000 | 9,434,622 |
| 3 | Rapt Therapeutics | 2024 | Brian Wong | 630,000 | 0 | 5,927,297 | 416,000 | 6,979,539 |
| 4 | CytomX Therapeutics | 2025 | Sean McCarthy | 675,290 | 1,150,463 | 2,158,170 | 749,572 | 4,738,495 |
| 5 | Bolt Therapeutics | 2025 | William Quinn | 463,500 | 224,400 | 3,668,768 | 0 | 4,558,368 |
| 6 | Whitehawk Therapeutics | 2025 | David Lennon | 676,504 | 1,318,907 | 973,664 | 0 | 3,359,075 |
| 7 | Protara Therapeutics | 2025 | Jesse Shefferman | 654,888 | 294,450 | 1,277,216 | 351,184 | 2,655,774 |
| 8 | Werewolf Therapeutics | 2024 | Daniel Hicklin | 608,237 | 0 | 1,559,867 | 0 | 2,545,599 |
| 9 | ALX Oncology Holdings | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 10 | Precision BioSciences | 2025 | Michael Amoroso | 650,875 | 1,025,086 | 0 | 0 | 2,189,467 |
| 11 | Kyntra BIO | 2025 | Thane Wettig | 665,000 | 0 | 846,023 | 580,545 | 2,113,842 |
| 12 | PMV Pharmaceuticals | 2025 | David Mack | 628,461 | 0 | 752,320 | 284,410 | 1,665,191 |
| 13 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 14 | Chimerix | 2023 | Mike Andriole | 528,473 | 93,135 | 399,282 | 280,500 | 1,312,421 |
| 15 | Actinium Pharmaceuticals | 2025 | Sandesh Seth | 762,320 | 0 | 0 | 0 | 1,187,320 |
| 16 | Hookipa Pharma | 2023 | Joern Aldag | 567,451 | 0 | 282,088 | 280,888 | 1,130,427 |
| 17 | Rallybio | 2024 | Stephen Uden | 551,200 | 0 | 314,626 | 248,040 | 1,127,666 |
| 18 | Celularity | 2024 | Robert Hariri | 179,140 | — | 634,563 | — | 848,959 |
| 19 | PDS Biotechnology | 2025 | Frank Bedu-Addo | 615,322 | 0 | 193,500 | 0 | 828,307 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Kyntra BIO | 116.4% | Options 100 | not disclosed | Compensia, Inc. |
| Actinium Pharmaceuticals | not disclosed | not disclosed | not disclosed | StreeterWyatt Analytics LLC |
| ALX Oncology Holdings | not disclosed | not disclosed | not disclosed | Compensia |
| Bolt Therapeutics | not disclosed | not disclosed | not disclosed | Aon plc (Radford) |
| Celularity | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | not disclosed |
| Chimerix | 85% | Option 86 · RSU 14 | not disclosed | Aon |
| CytomX Therapeutics | not disclosed | not disclosed | not disclosed | Aon |
| Eagle Pharmaceuticals | 75% | PSU 75 · RSU 25 | Yes — Total Shareholder Return (TSR) relative to S&P 600 Biotech Select Index (rTSR) | Compensia |
| Hookipa Pharma | not disclosed | Option 100 | not disclosed | Aon Radford |
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| PDS Biotechnology | not disclosed | not disclosed | not disclosed | not disclosed |
| PMV Pharmaceuticals | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Precision BioSciences | 115% | RSU 100 | not disclosed | Aon |
| Protara Therapeutics | not disclosed | not disclosed | not disclosed | Aon Consulting, Inc. |
| Rallybio | not disclosed | Option 100 | not disclosed | not disclosed |
| Rapt Therapeutics | 120% | Option 100 | not disclosed | Aon plc/Radford |
| SAB Biotherapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Werewolf Therapeutics | not disclosed | Option 100 | not disclosed | Pearl Meyer & Partners, LLC |
| Whitehawk Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | 1,242,005 | 23,606 | 24,639 | 96.26% | Passed |
| 2025 | 2025-06-04 | 31,091,508 | 8,989,137 | 964,591 | 77.57% | Passed |
| 2024 | 2024-06-05 | 53,461,963 | 1,754,540 | 70,105 | 96.7% | Passed |
| 2023 | 2023-06-07 | 48,733,191 | 21,946,460 | 89,290 | 68.86% | Passed |
| 2022 | 2022-06-16 | 36,094,036 | 31,129,425 | 167,215 | 53.56% | Passed |
| 2021 | 2021-05-26 | 57,352,169 | 5,415,148 | 455,333 | 90.71% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-12 | 96.26%a |
| 2025 | 2025-06-04 | 77.57%b |
| 2024 | 2024-06-05 | 96.7%c |
a. Approved under the standard stated in the filing — “3, votes "For" and "Against" and abstentions will be counted, with abstentions having the same effect as "Against" votes.”.
b. Approved under the standard stated in the filing — “Abstentions will not be counted and will have no effect on the vote for Proposal No.”.
c. Approved under the standard stated in the filing — “3, and No.4, votes "For" and "Against" and abstentions will be counted, with abstentions having the same effect as "Against" votes.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Thane Wettig | Director | 2026-05-14 | A | 2,800 | $7 | $19,852 | Common | Form 4 ↗ |
| Thane Wettig | Director | 2026-05-14 | D | 2,800 | 7 | 19,852 | Common | Form 4 ↗ |
| David DeLucia | Chief Financial Officer | 2026-06-06 | D | 52 | 7 | 349 | Common | Form 4 ↗ |
| Thane Wettig | Director | 2026-06-06 | D | 198 | 7 | 1,329 | Common | Form 4 ↗ |
| Jeffrey L. Edwards | Director | 2026-06-12 | A | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James A. Schoeneck | Director | 2026-06-12 | A | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Maykin Ho | Director | 2026-06-12 | A | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Kauffman | Director | 2026-06-12 | A | 7,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David DeLucia | Chief Financial Officer | 2026-09-06 | D | 22 | 9 | 188 | Common | Form 4 ↗ |
| Thane Wettig | Director | 2026-09-06 | D | 209 | 9 | 1,787 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (47 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Thane Wettig. DEF 14A, filed 2026-04-27. Section “Named Executive Officer” · page 30. As printed: 2,113,842. View filing ↗
- Section 01, Christine Chung. DEF 14A, filed 2026-04-27. Section “Named Executive Officer”. As printed: 1,181,108. View filing ↗
- Section 01, David DeLucia. DEF 14A, filed 2026-04-27. Section “Named Executive Officer”. As printed: 1,110,999. View filing ↗
- Section 03, Thane Wettig RSU. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, David DeLucia RSU. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-16. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, James A. Schoeneck. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 174,112. View filing ↗
- Section 08, Jeffrey L. Edwards. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 111,612. View filing ↗
- Section 08, Maykin Ho. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 96,612. View filing ↗
- Section 08, Michael Kauffman. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 91,726. View filing ↗
- Section 08, Aoife Brennan. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 24,643. View filing ↗
- Section 08, Thane Wettig. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Thane Wettig 2026-05-14. Form 4, filed 2026-05-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thane Wettig 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David DeLucia 2026-06-06. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thane Wettig 2026-06-06. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey L. Edwards 2026-06-12. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James A. Schoeneck 2026-06-12. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Maykin Ho 2026-06-12. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Kauffman 2026-06-12. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David DeLucia 2026-09-06. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thane Wettig 2026-09-06. Form 4, filed 2026-09-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-16. Item 5.07 · say-on-pay result. As reported: 96.26% (votes for as printed: The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2026 definitive proxy statement filed on April 27, 2026: 1,242,005 shares of Common Stock voted for, 23,606 against, 24,639 abstaining, and 1,444,428 broker non-votes.). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-09. Item 5.07 · say-on-pay result. As reported: 77.57% (votes for as printed: The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2025 definitive proxy statement filed on April 25, 2025: 31,091,508 shares of Common Stock voted for, 8,989,137 against, 964,591 abstaining, and 26,318,711 broker non-votes.). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 96.7% (votes for as printed: The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2024 definitive proxy statement filed on April 24, 2024: 53,461,963 shares of Common Stock voted for, 1,754,540 against, and 70,105 abstaining.). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 330,900 + equity 0 + all other 0 = 330,900, summed across the director compensation table rows.
- Eagle Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2023-05-01. CEO total compensation as printed in Eagle Pharmaceuticals's own proxy. As printed: 10,520,577. View filing ↗
- SAB Biotherapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in SAB Biotherapeutics's own proxy. As printed: 9,434,622. View filing ↗
- Rapt Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-14. CEO total compensation as printed in Rapt Therapeutics's own proxy. As printed: 6,979,539. View filing ↗
- CytomX Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in CytomX Therapeutics's own proxy. As printed: 4,738,495. View filing ↗
- Bolt Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Bolt Therapeutics's own proxy. As printed: 4,558,368. View filing ↗
- Whitehawk Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Whitehawk Therapeutics's own proxy. As printed: 3,359,075. View filing ↗
- Protara Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protara Therapeutics's own proxy. As printed: 2,655,774. View filing ↗
- Werewolf Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Werewolf Therapeutics's own proxy. As printed: 2,545,599. View filing ↗
- ALX Oncology Holdings, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ALX Oncology Holdings's own proxy. As printed: 2,470,844. View filing ↗
- Precision BioSciences, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Precision BioSciences's own proxy. As printed: 2,189,467. View filing ↗
- Kyntra BIO (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Kyntra BIO's own proxy. As printed: 2,113,842. View filing ↗
- PMV Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in PMV Pharmaceuticals's own proxy. As printed: 1,665,191. View filing ↗
- Mersana Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. View filing ↗
- Chimerix, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Chimerix's own proxy. As printed: 1,312,421. View filing ↗
- Actinium Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-10-16. CEO total compensation as printed in Actinium Pharmaceuticals's own proxy. As printed: 1,187,320. View filing ↗
- Hookipa Pharma, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Hookipa Pharma's own proxy. As printed: 1,130,427. View filing ↗
- Rallybio, Section 10b CEO total. DEF 14A, filed 2025-04-07. CEO total compensation as printed in Rallybio's own proxy. As printed: 1,127,666. View filing ↗
- Celularity, Section 10b CEO total. DEF 14A, filed 2025-11-07. CEO total compensation as printed in Celularity's own proxy. As printed: 848,959. View filing ↗
- PDS Biotechnology, Section 10b CEO total. DEF 14A, filed 2026-06-26. CEO total compensation as printed in PDS Biotechnology's own proxy. As printed: 828,307. View filing ↗